Releases
24. July, 2026
Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu
See also the updated Q&A documentation related to the Release: Link The European Medicines...
Releases
12. June, 2026
Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet
Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ...
Releases
28. May, 2026
Financial Report Q1-2026
Cessatech today announced the interim report for the three months ended March 31, 2026....
Facts
12. March, 2026
Poster session: comparing the results of Study 0202 in children with simulated data from adults.
Thursday, March 12, 2026 Our Chief Scientific Officer, Martin Juhl, PhD, presented a poster...
Releases
27. February, 2026
Annual Report for 2025
Today, 27 February 2026, Cessatech publishes the Annual Report for 2025. 2025 was a...
Releases
2. February, 2026
Welcome to the first quarter of 2026
Welcome to the first quarter of 2026 2025 has been a year of significant...
Facts
2. December, 2025
Children deserve better prehospital pain treatment
A newly published registry study from the Region of Southern Denmark highlights a clear...
Releases
13. November, 2025
Financial Report Q3-2025
The Company has advanced well with its planned activities Closing the clinical and regulatory...
Releases
31. October, 2025
CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children
Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product...
Releases
21. August, 2025
Financial Report Q2-2025
The Company has advanced well with its planned activities Positive and clinical meaningful top-line...
Releases
14. August, 2025
Marketing Authorisation Application (MAA) for CT001 has been submitted to the European Medicines Agency (EMA) for acute pain management in children
The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency...
Releases
27. June, 2025
Cessatech Q&A – June company presentation
Selected top 5 summarized questions from investors… Q&A Cessatech_June